Description
The
125I- L-3,5,3'-triiodothyronine (T3) assay system provides
the quantitative in vitro determination of T3 in human serum in the
range of 0-12 nmol/l (0-780 ng/dl).
Introduction
Among the thyroid hormones produced in the thyroid gland
triiodothyronine (T3) is regarded as the most biologically active
molecule, produced up to 80% by the deiodination of tetraiodothyronine
(T4) in peripheral tissues.
T3
is found in the bloodstream in a major (99.7%) protein-bound, and a
minor (0.3%) unbound, fraction. Variations in total thyroid hormone in
blood may result from either changes of binding proteins concentrations,
or thyroid hormone production.
T3
contributes significantly to the maintenance of the euthyroid state, and
the total T3 level has a role in screening for thyroid disease in
conjuction with other tests. T3 alone cannot diagnose hypothyroidism,
but it may be more sensitive than T4 for hyperthyroidism.
Principle of method
This
assay is based on the competition between unlabelled T3 and fixed
quantity of 125I-labelled T3 for limited number of binding
sites on T3 specific antibody. Allowing to react a fixed amount of
tracer and antibody with different amounts of unlabelled ligand the
amount of tracer bound by the antibody will be inversely proportional to
the concentration of unlabelled ligand.
During a
2-hour incubation period with continuous agitation immuno-complex is
immobilized on the reactive surface of test tubes. After incubation the
reaction mixture is discarded, and the radioactivity is measured in a
gamma counter.
The
concentration of antigen is inversely proportional to the radioactivity
measured in test tubes. By plotting binding values against a series of
calibrators containing known amount of T3, a calibration curve is
constructed, from which the unknown concentration of T3 in patient
samples can determined.
Contents of the kit
|
1 vial |
125I-TRACER
11 ml, containing less than 260 kBq 125I-T3 in buffer
with red dye and 0.1% NaN3 |
|
6 vials |
STANDARDS, ready to use.
0.5 ml per vial, containing 0; 0.5; 1.5; 3.0; 6.0; 12.0 nmol/l
in human serum with 0.1% NaN3 |
|
1 bottle |
ANTISERUM, ready to use.
105 ml, containing monoclonal anti-T3 IgG in buffer with blue
dye and 0.01% thimerosal. |
|
1 vial |
CONTROL SERUM.
Lyophilized human serum with 0.1% NaN3.
The concentration of the serum is specified in the quality
certificate enclosed. |
|
2 boxes |
COATED TUBE, ready to use.
2 x 50 reactive test tubes, 12x75 mm, packed in plastic boxes. |
|
1 pc |
Quality certificate |
|
1 pc |
Pack leaflet |
Materials, tools and equipment required
Test
tube rack
Precision pipettes with disposable tip (100 and 1000 µl)
Shaker
Plastic foil
Absorbent tissue
Gamma counter
Recommended tools and equipment
Repeating pipettes (e.g. Eppendorf)
Specimen collection and storage
Serum
samples can be prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored at 2-8 °C if the
assay is carried out within 24 hours, otherwise aliquots should be
prepared and stored deep frozen (-20 °C). Frozen samples should be
thawed and thoroughly mixed before assaying. Repeated freezing and
thawing should be avoided.
Do not
use lipemic, hemolyzed or turbid specimens.
Preparation of reagents, storage
Store
the reagents between 2-8 °C after opening. At this temperature each
reagent is stable until expiry date. The actual expiry date is given on
the package label and in the quality certificate.
Add 500
µl distilled water to the lyophilized control serum. Mix gently with
shaking or vortexing (foaming should be avoided).
Ensure
that complete dissolution is achieved, and allow the solution to
equilibrate at room temperature for at least 20 minutes. Store at 2-8 °C
until expiry date.
CAUTION! Equilibrate all reagents and serum samples to room temperature.
Mix all reagents and samples thoroughly before use. Avoid excessive
foaming.
Assay procedure
(For a
quick guide refer to Table 1)
|
1 |
Equilibrate reagents and samples to room temperature
before use (min. for an hour). |
|
2 |
Label
coated tubes in duplicate for each standard (S1-S6), control
serum (C) and samples (M). Optionally, label two test tubes for
total count (T). |
|
3 |
Homogenize all reagents and samples by gentle mixing to
avoid foaming. |
|
4 |
Pipette 100 µl each of standards, control and samples
into the properly labelled tubes. |
|
5 |
Pipette 100 µl of tracer into each tube. |
|
6 |
Pipette 1000 µl of antiserum into each tube except T.. |
|
7 |
Fix the test tube rack firmly onto the shaker plate. Seal
all tubes with a plastic foil. Turn on the shaker and adjust an
adequate speed such that liquid is constantly rotating or
shaking in each tube. |
|
8 |
Incubate tubes for 2 hours at room temperature. |
|
9 |
Aspirate or decant the supernatant from all tubes by the
inversion of the rack. In the upside down position place the
rack on an absorbent paper for 2 minutes. |
|
10 |
Count each tube for at least 60 seconds in a gamma
counter. |
|
11 |
Calculate the T3 concentrations of the samples as
described in Calculation of results. |
Table
1. Assay Protocol, Pipetting Guide (all volumes in microliters)
|
Tubes
Reagents |
Total
count
(T) |
Standard
(S1-S6) |
Sample
(M) |
Control
(C) |
|
Standard |
|
100 |
|
|
|
Sample |
|
|
100 |
|
|
Control |
|
|
|
100 |
|
Tracer |
100 |
100 |
100 |
100 |
|
Antiserum |
|
1000 |
1000 |
1000 |
|
Shake
for 2 hours at room temperature. |
|
Decant
the fluid and blot on filter paper |
|
Count
radioactivity (60 sec/tube) |
|
Calculate the results |
Calculation of results
The
calculation is illustrated using representative data. The assay data
collected should be similar to those shown in Table 2.
Calculate the average counts per minute (CPM) for each pair of assay
tubes. Calculate the percent B0 / T for zero standard (S1)
by using the following equation:
| |
S1 (cpm) |
|
|
B0 / T % = |
——— |
x 100 |
| |
T (cpm) |
|
B0/T%
is an optional quality control parameter unnecessary for determination
of sample concentrations. Calculate the normalized percent binding for
each standard, control and sample respectively by using the following
equation:
| |
S2-6 [C, Mx] (cpm) |
|
|
B /
B0 % =
|
—————————— |
x 100 |
| |
S1 (cpm) |
|
For
simplicity, these values are uncorrected for non-specific binding (NSB).
This is enabled by low NSB being less than 3% of total count. Using
semi-logarithmic graph paper plot B /
B0 % for each standard versus the corresponding
concentration of T3. Figure 1 shows a typical standard curve.
Determine the T3 concentration of the unknown samples by interpolation
from the standard curve. Do not extrapolate values beyond the standard
curve range.
Out of
fitting programs applied for computerized data processing logit-log, or
spline fittings can be used.
Table
2. Typical Assay Data
|
Tubes |
Count
cpm |
Average
cpm |
B0 / T
% |
B / B0
% |
|
T |
82800
82414 |
82607 |
|
|
|
S1 |
41973
40338 |
41156 |
49.8 |
100.0 |
|
S2 |
35009
36386 |
35698 |
43.2 |
86.7 |
|
S3 |
29766
29650 |
29708 |
36.0 |
72.2 |
|
S4 |
23583
23702 |
23643 |
28.6 |
57.4 |
|
S5 |
15502
16145 |
15824 |
19.2 |
38.4 |
|
S6 |
9973
10191 |
10082 |
12.2 |
24.5 |
|
C |
28840
28936 |
28888 |
35.0 |
70.2 |
T3 concentration nmol/l
Figure 1.
A typical standard curve
(Do not use to calculate sample values)
Characterization of the assay
Assay
parameters
|
B0 / T |
|
45 ± 6
% |
|
ED-80 |
|
4.5 ±
0.9 nmol/l |
Specificity
Cross
reactivity values are shown below.
|
3,5,3'-L-triiodothyronine (T3) |
100% |
|
Thyroxine (T4) |
<
0.06% |
|
3’,5’,3,-triodo-L-thyronine (rT3) |
<
0.016% |
|
3,3’-diiodo-L-thyronine (3,3’-T2) |
< 1.9% |
Sensitivity
Better
than 0.3 nmol/l, corresponding to the 0-2xSD value.
Precision
5
control samples were assayed in 10 replicates to determine intraassay
precision. Values obtained are shown below.
|
Sample |
Mean value
nmol/l |
SD
nmol/l |
CV
% |
|
1 |
1.83 |
0.11 |
5.8 |
|
2 |
2.06 |
0.12 |
5.9 |
|
3 |
2.29 |
0.10 |
4.5 |
|
4 |
3.10 |
0.19 |
6.0 |
|
5 |
9.32 |
0.46 |
5.0 |
Reproducibility
To
determine interassay precision 5 control samples were measured in
duplicates in 7 independent assays. Values obtained are shown below.
|
Sample |
Mean value
nmol/l |
SD
nmol/l |
CV
% |
|
1 |
0.91 |
0.10 |
10.6 |
|
2 |
1.72 |
0.07 |
4.3 |
|
3 |
1.76 |
0.08 |
4.6 |
|
4 |
2.37 |
0.10 |
4.0 |
|
5 |
4.31 |
0.17 |
3.9 |
Recovery
Recovery was defined as the measured increase expressed as percent of
expected increase upon spiking serum samples with known amount of T3.
The mean (± SD) recovery % for added T3 (5 samples, 2.5 nM added T3) was
102.1 ± 3.9.
Expected reference values
It is recommended that each laboratory establish its own reference
intervals. The expected values presented here are based on testing of
apparently healthy blood donors. Samples were measured in duplicates.
In a
population (n = 120) of adult female blood donors serum
concentrations of T3 were 2.18 ± 0.5 (as mean ± SD). Sample values were
found scattered in a range of (1.25 - 3.91). As a guide, 1.4 - 3.3
nmol/l (91 – 215 ng/dl) can be interpreted as reference range for normal
patients.
In a
population (n = 118) of adult male blood donors serum
concentrations of T3 were 1.80 ± 0.38 (as mean ± SD). Sample values were
found scattered in a range of (0.55 – 2.75). As a guide, 1.0 – 2.6
nmol/l (65 – 169 ng/dl) can be interpreted as reference range for normal
patients.
For
female and male (n = 238) the mean (± SD) serum concentration of T3 was
1.99 ± 0.49 in a range (0.55 - 3.91). As a guide, 1.0 - 3.3 nmol/l (65 –
214.5 ng/dl) reference range was obtained from normal patients.
The
results obtained should only be interpreted in the context of the
overall clinical picture. None of the in vitro diagnostic kits can be
used as the one and only proof of any disease or disorder.
Conversion of SI units can be performed according to
the following formula:
1
nmol/l = 0.65 ng/ml
1 ng/ml = 1.54 nmol/l
Procedural notes
1)
Source of error! Reactive test tubes packed in plastic
boxes are not marked individually. Care should be taken of not mixing
them with common test tubes. To minimize this risk, never take more
tubes than needed out of plastic box, and put those left after work back
to the box. It is recommended to label assay tubes by a marker pen.
2)
Source of error! To ensure the efficient rotation,
tubes should be firmed tightly inside the test tube rack. Never use a
rack type with open hole. An uneven or incomplete shaking may result in
a poor assay performance.
Additional information
Components from various lots or from kits of different manufacturers
should not be mixed or interchanged.
Precaution
Radioactivity
This
product contains radioactive material. It is the responsibility of the
user to ensure that local regulations or code of practice related to the
handling of radioactive materials are satisfied.
Biohazard
Human
blood products used in the kit have been obtained from healthy human
donors. They were tested individually by using approved methods (EIA,
enzyme immunoassay), and were found to be negative, for the presence of
both Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B
surface Antigen (HBsAg).
Care
should always be taken when handling human specimens to be tested with
diagnostic kits. Even if the subject has been tested, no method can
offer complete assurance that Hepatitis B Virus, Human Immunodeficiency
Virus (HIV-1), or other infectious agents are absent. Human blood
samples should therefore be handled as potentially infectious
materials.
Chemical hazard
Components contain sodium azide as an antimicrobial agent. Dispose of
waste by flushing with copious amount of water to avoid build-up of
explosive metallic azides in copper and lead plumbing. The total azide
present in each pack is 14.5 mg.
 |
Use by |
 |
In vitro diagnostic medical device |
 |
Control |
 |
Batch code |
 |
Manufacturer |
 |
Standard |
 |
Caution, consult accompanying documents |
 |
Radioactive material |
 |
Coated tube |
 |
Biological risk |
 |
Temperature limitation
Store between 2-8 °C |
 |
Tracer |
 |
Consult instructions for use |
 |
Catalogue number |
 |
Antiserum |
|